>
Organization
Sumitomo Dainippon Pharma
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed

News on Sumitomo Dainippon Pharma

... Japan-based Sumitomo Dainippon Pharma has published positive results from the phase III JEWEL trial into ...
... dysfunction, in the U.S., Europe and Japan. Together, with our partner Sumitomo Dainippon Pharma, we are conducting the Phase 3 Trials of IMeglimin for Efficacy ...
... Chief Medical Officer at Sunovion, Head of Global Clinical Development for Sumitomo Dainippon Pharma Group. "As a part of our commitment to developing new treatments ...
... Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi ...
... dysfunction, in the U.S., Europe and Japan. Together, with our partner Sumitomo Dainippon Pharma, we are conducting the Phase 3 Trials of Imeglimin for Efficacy ...
... dysfunction, in the U.S., Europe and Japan. Together, with our partner Sumitomo Dainippon Pharma, we are conducting the Phase 3 Trials of IMeglimin for Efficacy ...
... Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi ...
... Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi ...
... 9 months Roivant Agreement 8.1 - - 8.1 - - - - Sumitomo Agreement 10.2 19.2 17.5 46.9 - - - - Total revenues 18.3 ...
... "In less than one year after signing the strategic partnership with Sumitomo Dainippon Pharma, we have made substantial progress advancing all three pivotal Phase 3 ...
Subscribe now for full coverage on Sumitomo Dainippon Pharma
Start My Free Trial